COMP <GO>
LIVN vs ABBV // NET PROFIT MARGIN
LivaNova PLC (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: LIVN 3
— ABBV 8
▲ NET PROFIT MARGIN LEADER: ABBV
LAST: $81.25 (+0.73%) • MKT CAP: $4.48B
net-margins
-17.50%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
net-margins
6.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LIVN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LIVN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.70% | 70.20% | -2.50 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.30% | 29.00% | -11.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.6x | 33.3x | -17.70 | LIVN | /valuation <GO> |
| Free Cash Flow Yield | 3.87% | 3.47% | +0.40 | LIVN | /fcf-yield <GO> |
| Operating Margin | 14.40% | 24.60% | -10.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -17.50% | 6.90% | -24.40 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 10.70% | 8.60% | +2.10 | LIVN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.21 | 5.33 | -3.12 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.2 | 65.1 | -6.90 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.48B | $513.86B | -$509.38B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LIVN REV | ABBV REV | LIVN GROSS % | ABBV GROSS % | LIVN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.39B | $61.16B | 67.7% | 70.2% | $173.3M | $17.82B |
| FY 2024 | $1.25B | $56.33B | 68.1% | 70.0% | $135.9M | $17.83B |
| FY 2023 | $1.15B | $54.32B | — | — | $74.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LIVN // BETA —
ABBV // BETA 1.15